Nicotinamide riboside tartrate
Modify Date: 2024-01-10 06:18:45
Nicotinamide riboside tartrate structure
|
Common Name | Nicotinamide riboside tartrate | ||
|---|---|---|---|---|
| CAS Number | 2415657-86-0 | Molecular Weight | 404.33 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C15H20N2O11 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Nicotinamide riboside tartrateNicotinamide riboside tartrate, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2]. |
| Name | Nicotinamide riboside tartrate |
|---|
| Description | Nicotinamide riboside tartrate, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2]. |
|---|---|
| Related Catalog | |
| Target |
SIRT1 SIRT3 |
| In Vitro | Nicotinamide riboside tartrate (0.5 nM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2[1]. Nicotinamide riboside tartrate increases intracellular and mitochondrial NAD+ content in C2C12, Hepa1.6, and HEK293 cells in a concentration-dependent manner at concentrations ranging from 1-1000 μM[1]. Nicotinamide riboside tartrate boosts NAD to restore antiviral poly(ADP-ribose) polymerase (PARP) functions to support innate immunity for coronavirus (CoVs), a cause of COVID-19[3]. Western Blot Analysis[1] Cell Line: HEK293T cells Concentration: 0.5 nM Incubation Time: 24 hours Result: Reduced the acetylation status of Ndufa9 and SOD2. |
| In Vivo | Chronic Nicotinamide riboside tartrate (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD+ content in a tissue-specific manner[1]. Animal Model: 10-week-old C57Bl/6J mice[1] Dosage: 400 mg/kg Administration: PO; daily; for 16 weeks Result: Increased plasma and intracellular NAD+ content in a tissue-specific manner. |
| References |
| Molecular Formula | C15H20N2O11 |
|---|---|
| Molecular Weight | 404.33 |